Drug intelligence / Profile preview

GO-R800

Development stage: Preclinical
Lead developer: GO Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GO-R800 is an investigational monoclonal antibody developed by GO Therapeutics for the treatment of multiple solid tumors. It is part of a therapeutic platform that targets tumor-associated truncated O-glycans, specifically the Tn (N-acetylgalactosamine-serine/threonine) and STn (Sialyl-Tn) antigens. These glycans are considered highly specific tumor markers because they are frequently overexpressed in various cancers due to aberrant glycosylation but are absent or minimally expressed in healthy tissues. By targeting these "super-clean" antigens, GO-R800 is designed to selectively bind and eliminate malignant cells while minimizing off-target toxicity. The program is currently in early-stage development.

Targets

STn-MUC1 (Sialyl-Tn-MUC1)Tn (Tn antigen)

Beyond the preview

Go deeper on GO-R800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO-R800.

Explore the full profile